Inclusive Trials

Inclusive Trials Are Better Trials: Why Women’s Health Can’t Be a Footnote Anymore

Emilee Kudla

That's Nice LLC

Sex Differences

Half the Data, Half the Science: The Cost of Ignoring Sex Differences in Preclinical Research

David Alvaro, Ph.D.

Pharma's Almanac

DSCSA

Understanding the Drug Supply Chain Security Act

Leandro Moreira

Frontier Scientific Solutions

Food Dyes

What’s Really in Your Rainbow Cereal? The Truth About Synthetic Food Dyes and Why They’re (Finally) Getting the Boot

Emilee Kudla

That's Nice LLC

Animal Testing

The End of an Era: What the FDA's Move Away from Animal Testing Means for Biopharma

Daniel Smith, Ph.D.

Nice Consulting

RNA

Is mRNA a Gene Therapy? Unpacking the Evolving Regulatory Debate

Cynthia A. Challener, Ph.D.; April Stanley, MS MBA

Pharma's Almanac

Drug Approvals

How can the industry balance the need for faster drug approvals with the necessity of ensuring patient safety and efficacy?

Pharma's Almanac

Global Trials

Clinical Trials Without Borders: The Evolution of Global Drug Development

David Alvaro, Ph.D.

Pharma's Almanac

Advocacy

From Patients to Partners: The Rising Power of Advocacy in Drug Development

David Alvaro, Ph.D.

Pharma's Almanac

Accelerated Approval

30 Years of Accelerated Approvals: Fast-Tracking Innovation in Drug Development

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Orphan Drugs

From Market Failures to Lifesaving Innovations: The Evolution of Orphan Drugs

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Federal Job Cuts

Science Under Siege: The Devastating Consequences of Public Health and Research Cuts

David Alvaro, Ph.D.

Pharma's Almanac